References
1. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006;55(3):426-31. DOI: 10.1136/gut.2005.069476
2. Gisbert JP, González Lama Y, Maté J. Role of biological markers in inflammatory bowel disease. Gastroenterol Hepatol 2007;30(3):117-29. DOI: 10.1157/13100073
3. Vieira A, Fang CB, Rolim EG, et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Notes 2009;2:221.
4. Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450-60.
5. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early stage Crohn’s disease. Gastroenterology 2010;138:463-8.
6. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194-201.
7. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004;10:661-5.
8. Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective longitudinal study. Gut 2008;57:1518-23.
9. Oyaert M, Boel A, Jacobs J, et al. Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease. Clin Chem Lab Med 2017;55:1564-73.
10. Labaere D, Smismans A, Van Olmen A, et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J 2014;2:30-7.
11. Coorevits L, Baert FJ, Vanpoucke HJ. Fecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method. Clin Chem Lab Med 2013;51:825-31.
12. Mee AS, Berney J, Jewell DP. Monocytes in inflammatory bowel disease: absolute monocyte counts. J Clin Pathol 1980;33:917-20.
13. Zhou L, Braat H, Faber KN, et al. Monocytes and their pathophysiological role in Crohn’s disease. Cell Mol Life Sci 2009;66:192-202.
14. Thayer WR Jr, Charland C, Field CE. The subpopulations of circulating white blood cells in inflammatory bowel disease. Gastroenterology 1976;71:379-84.
15. Jakubzick C, Gautier EL, Gibbings SL, et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity 2013;39:599-610.
16. Cherfane C, Anderson AJ, Ramos Rivers C, et al. Is monocytosis a biomarker of severity in inflammatory bowel disease? Analysis of a 6 year, prospective natural history registry. Gastroenterology 2016;150(4):S42. DOI: 10.1016/S0016-5085(16)30266-9
17. Cherfane C, Gessel L, Dominic C, et al. Monocytosis and a low lymphocyte to monocyte ratio are effective biomarkers of ulcerative colitis disease activity. Inflamm Bowel Dis 2015;21:1769-75.
18. Silverberg MS, Satsangi J, Ahmad T, et al. Towards an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of gastroenterology. Can J Gastroenterol 2005;19(suppl A):5A-36A. DOI: 10.1155/2005/269076
19. Mee AS, Berney J, Jewell DP. Monocytes in inflammatory bowel disease: absolute monocyte counts. J Clin Pathol 1980;33:917-20.
20. Zhou L, Braat H, Faber KN, et al. Monocytes and their pathophysiological role in Crohn’s disease. Cell Mol Life Sci 2009;66:192-202.
21. La Manna MP, Orlando V, Dieli F, et al. Quantitative and qualitative profiles of circulating monocytes may help identifying tuberculosis infection and disease stages. Plos One 2017;12(2):e0171358. DOI: 10.1371/journal.pone.0171358
22. Wei XB, Chen F, Huang JL, et al. Novel risk biomarker for infective endocarditis patients with normal ventricular ejection fraction – monocyte to high density lipoprotein colesterol ratio. Cir J 2007;82:283-8.
23. Woollard KJ, Geissman F. Monocytes in aterosclerosis: subsets and functions. Nat Rev Cardiol 2010;7:77-86.
24. Dutta P, Nahrendorf M. Monocytes in myocardial infarction. Arterioscler Thromb Vasc Biol 2015;35:1066-70.
25. Klimek E, Mikolajcyk T, Sulicka J, et al. Blood monocyte subsets and selected cardiovascular risk markers in rheumatoid arthritis of short duration in relation to disease activity. Biomed Res Int 2014;2014:736853.
26. Hensel M, Grädel L, Kutz A, et al. Peripheral monocytosis as a predictive factor for adverse outcome in the emergency department. Medicine 2017;96:e7404. DOI: 10.1097/MD.0000000000007404
27. García-Sánchez V, Iglesias-Flores E, González R, et al. Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohns Colitis 2010;4(2):144-52. DOI: 10.1016/j.crohns.2009.09.008
28. Gisbert JP, Bermejo F, Pérez-Calle JL, et al. Fecal calprotectin and lactoferrin for the prediction of inflam- matory bowel disease relapse. Inflamm Bowel Dis 2009;15:1190-8.
29. Lobatón T, López-García A, Rodríguez-Moranta F, et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease. J Crohns Colitis 2013;7:641-51.
30. Lobatón T, Rodríguez-Moranta F, Lopez A, et al. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis 2013;19:1034-42.
31. Ferreiro-Iglesias R, Barreiro-de Acosta M, Lorenzo A, et al. Fecal calprotectin as predictor of relapse in patients with inflammatory bowel disease under maintenance infliximab therapy. J Clin Gastroenterol 2016;50:147-51.
32. Ferreiro Iglesias R, Barreiro de Acosta M, Lorenzo Gonzalez A, et al. Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn’s disease patients on maintenance treatment with adalimumab. Scand J Gastroenterol 2016;51:442-7.
33. Ferreiro Iglesias R, Barreiro de Acosta M, Lorenzo A, et al. Accuracy of consecutive fecal calprotectin measurements to predict relapse in inflammatory bowel disease patients under maintenance with anti-TNF therapy: a prospective longitudinal cohort study. J Clin Gatroenterol 2018;52:229-34.
34. Valenzuela JE, Pereñiguez Lopez A, Perez Fernandez V, et al. Fecal calprotectin and C-reactive protein are associated with positive findings in capsule endoscopy in suspected small bowel Crohn’s disease. Rev Esp Enferm Dig 2016;108:394-400. DOI: 10.17235/reed.2016.4318/2016